OTCPK:RSLS

Stock Analysis Report

Executive Summary

ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Risks

  • ReShape Lifesciences has significant price volatility in the past 3 months.
  • ReShape Lifesciences is not covered by any analysts.

Similar Companies

Share Price & News

How has ReShape Lifesciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-6.7%

OTCPK:RSLS

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

-99.2%

OTCPK:RSLS

8.7%

US Medical Equipment

1.7%

US Market

RSLS underperformed the Medical Equipment industry which returned 8.7% over the past year.

RSLS underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

RSLSIndustryMarket
7 Day-6.7%-1.2%1.2%
30 Day-12.5%1.4%4.9%
90 Day33.3%4.8%3.7%
1 Year-99.2%-99.2%9.6%8.7%3.9%1.7%
3 Year-100.0%-100.0%70.8%65.5%47.2%37.7%
5 Year-100.0%-100.0%130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is ReShape Lifesciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ReShape Lifesciences undervalued based on future cash flows and its price relative to the stock market?

0.15x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for ReShape Lifesciences to establish if it is available at moderate discount.

Unable to calculate intrinsic value for ReShape Lifesciences to establish if it is available at substantial discount.


Price Based on Earnings

ReShape Lifesciences is loss making, we can't compare its value to the US Medical Equipment industry average.

ReShape Lifesciences is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for ReShape Lifesciences, we can't assess if its growth is good value.


Price Based on Value of Assets

ReShape Lifesciences is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is ReShape Lifesciences expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ReShape Lifesciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of RSLS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access ReShape Lifesciences's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has ReShape Lifesciences performed over the past 5 years?

-8.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

ReShape Lifesciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare ReShape Lifesciences's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare ReShape Lifesciences's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if ReShape Lifesciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if ReShape Lifesciences has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if ReShape Lifesciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is ReShape Lifesciences's financial position?


Financial Position Analysis

ReShape Lifesciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

ReShape Lifesciences's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

ReShape Lifesciences's level of debt (0%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (33.6% vs 0% today).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are -1.1376993378663E+17x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

ReShape Lifesciences has less than a year of cash runway based on current free cash flow.

ReShape Lifesciences has less than a year of cash runway if free cash flow continues to grow at historical rates of 7.5% each year.


Next Steps

Dividend

What is ReShape Lifesciences's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate ReShape Lifesciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate ReShape Lifesciences's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as ReShape Lifesciences has not reported any payouts.

Unable to verify if ReShape Lifesciences's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as ReShape Lifesciences has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of ReShape Lifesciences's salary, the management and board of directors tenure and is there insider trading?

1.6yrs

Average management tenure


CEO

Bart Bandy (58yo)

0.4yrs

Tenure

0

Mr. Barton P. Bandy, also known as Bart, has been the President and Chief Executive Officer of ReShape Lifesciences Inc. since April 1, 2019 and has been its Director since May 8, 2019. Mr. Bandy served as ...


Management Age and Tenure

1.6yrs

Average Tenure

58yo

Average Age

The average tenure for the ReShape Lifesciences management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.3yrs

Average Tenure

61yo

Average Age

The average tenure for the ReShape Lifesciences board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$3,77504 Sep 19
Armistice Capital LLC
EntityCompany
Shares53,928
Max PriceUS$0.07
BuyUS$14,00029 Aug 19
Armistice Capital LLC
EntityCompany
Shares200,000
Max PriceUS$0.07
BuyUS$25,50009 Aug 19
Armistice Capital LLC
EntityCompany
Shares350,000
Max PriceUS$0.08
BuyUS$3,50026 Jul 19
Armistice Capital LLC
EntityCompany
Shares50,000
Max PriceUS$0.07
BuyUS$36,00026 Jul 19
Armistice Capital LLC
EntityCompany
Shares450,000
Max PriceUS$0.08
BuyUS$2,81504 Feb 19
Sabby Management, LLC
EntityCompany
Shares10,301
Max PriceUS$0.27
BuyUS$16,83031 Jan 19
Sabby Management, LLC
EntityCompany
Shares60,200
Max PriceUS$0.28
BuyUS$5,81628 Jan 19
Sabby Management, LLC
EntityCompany
Shares21,785
Max PriceUS$0.27
BuyUS$1,60924 Jan 19
Sabby Management, LLC
EntityCompany
Shares5,766
Max PriceUS$0.28
BuyUS$6,80122 Jan 19
Sabby Management, LLC
EntityCompany
Shares24,386
Max PriceUS$0.28
BuyUS$46,61317 Jan 19
Sabby Management, LLC
EntityCompany
Shares194,421
Max PriceUS$0.27

Ownership Breakdown


Management Team

  • Mark Knudson (70yo)

    Co-Founder and Special Advisor to the CEO

    • Tenure: 0yrs
    • Compensation: US$396.98k
  • Scott Youngstrom (59yo)

    CFO, Senior VP of Finance & Secretary

    • Tenure: 2.9yrs
    • Compensation: US$1.16m
  • Katherine Tweden (58yo)

    Co-Founder

    • Tenure: 0yrs
    • Compensation: US$240.67k
  • Bart Bandy (58yo)

    President

    • Tenure: 0.4yrs
  • Vipul Shah

    Senior Vice President of Operations and R&D

    • Tenure: 1.6yrs
  • Raj Nihalani (49yo)

    Chief Technology Officer

    • Tenure: 2.3yrs
  • Jody Dahlman

    Director of Communications

    • Tenure: 0yrs
  • Kevin Condrin

    Senior Vice President of Commercial

    • Tenure: 0.3yrs

Board Members

  • Dan Gladney (66yo)

    Chairman of the Board

    • Tenure: 2.9yrs
    • Compensation: US$3.01m
  • Gary Blackford (62yo)

    Lead Director

    • Tenure: 2.8yrs
    • Compensation: US$89.83k
  • Phil Schauer

    Member of Scientific Advisory Board

    • Tenure: 1.3yrs
  • Bart Bandy (58yo)

    President

    • Tenure: 0.4yrs
  • Scott Shikora (60yo)

    Member of Scientific Advisory Board

    • Tenure: 1.3yrs
    • Compensation: US$892.19k
  • Lori McDougal (58yo)

    Director

    • Tenure: 4.2yrs
    • Compensation: US$69.73k
  • Jaime Ponce

    Member of Scientific Advisory Board

    • Tenure: 1.3yrs
  • John Morton

    Member of Scientific Advisory Board

    • Tenure: 1.3yrs
  • Natan Zundel

    Member of Scientific Advisory Board

    • Tenure: 1.3yrs
  • Arda Minocherhomjee (65yo)

    Director

    • Tenure: 1.1yrs
    • Compensation: US$36.00k

Company Information

ReShape Lifesciences Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ReShape Lifesciences Inc.
  • Ticker: RSLS
  • Exchange: OTCPK
  • Founded: 2002
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$2.359m
  • Shares outstanding: 33.71m
  • Website: https://www.reshapelifesciences.com

Number of Employees


Location

  • ReShape Lifesciences Inc.
  • 1001 Calle Amanecer
  • San Clemente
  • California
  • 92673
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RSLSOTCPK (Pink Sheets LLC)YesCommon StockUSUSDNov 2007

Biography

ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 00:11
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.